scholarly journals The inhibition of KDM2B promotes the differentiation of basal-like breast cancer cells via the posttranslational destabilization of SLUG

2020 ◽  
Author(s):  
Elia Aguado Fraile ◽  
Evangelia Chavdoula ◽  
Georgios I. Laliotis ◽  
Vollter Anastas ◽  
Oksana Serebrennikova ◽  
...  

ABSTRACTKDM2B is a JmjC domain H3K36me2/H3K36me1 demethylase, which immortalizes cells in culture and contributes to the biology of both embryonic and adult stem and progenitor cells. It also functions as an oncogene that contributes to the self-renewal of breast cancer stem cells by regulating polycomb complexes. Here we show that the silencing of KDM2B results in the downregulation of SNAI2 (SLUG), SNAI1 (SNAIL) and SOX9, which also contribute to the biology of mammary stem and progenitor cells. The downregulation of these molecules is posttranscriptional and in the case of the SNAI2-encoded SLUG, it is due to calpain-dependent proteolytic degradation. Mechanistically, the latter depends on the activation of calpastatin-sensitive classical calpain(s) and on the phosphorylation-dependent inhibition of GSK3 via paracrine mechanisms. GSK3 inhibition sensitizes its target SLUG to classical calpains, which are activated by Ca2+ influx and calpastatin downregulation. The degradation of SLUG, induced by the KDM2B knockdown, promotes the differentiation of breast cancer stem cells in culture and reveals an unexpected mechanism of stem cell regulation by a histone demethylase.

2008 ◽  
Vol 2008 ◽  
pp. 1-12 ◽  
Author(s):  
Claudia Casarsa ◽  
Saro Oriana ◽  
Danila Coradini

Breast cancer remains a leading cause of morbidity and mortality in women mainly because of the propensity of primary breast tumors to metastasize. Growing experimental evidence suggests that cancer stem cells (CSCs) may contribute to tumor progression and metastasis spread. However, despite the tremendous clinical potential of such cells and their possible therapeutic management, the real nature of CSCs remains to be elucidated. Starting from what is currently known about normal mammary stem/progenitor cells, to better define the cell that originates a tumor or is responsible for metastatic spread, this review will discuss experimental evidence of breast cancer stem cells and speculate about the clinical importance and implications of their evaluation.


Oncotarget ◽  
2019 ◽  
Vol 10 (48) ◽  
pp. 5003-5004 ◽  
Author(s):  
Annalisa Petrelli ◽  
Rosachiara Carollo ◽  
Marilisa Cargnelutti ◽  
Flora Iovino ◽  
Maurizio Callari ◽  
...  

2011 ◽  
Vol 133 (2) ◽  
pp. 437-445 ◽  
Author(s):  
Angelina I. Londoño-Joshi ◽  
Patsy G. Oliver ◽  
Yufeng Li ◽  
Choo Hyung Lee ◽  
Andres Forero-Torres ◽  
...  

Oncotarget ◽  
2014 ◽  
Vol 6 (4) ◽  
pp. 2315-2330 ◽  
Author(s):  
Annalisa Petrelli ◽  
Rosachiara Carollo ◽  
Marilisa Cargnelutti ◽  
Flora Iovino ◽  
Maurizio Callari ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document